Bioscience

InNexus Biotechnology amends collaborative agreement with the National Cancer Institute (NCI)

July 1, 2010

By Flinn Foundation

[Source: EON] – InNexus Biotechnology Inc., a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company and the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), have amended the Collaborative Agreement announced on May 27, 2010, involving research on technologies developed by InNexus.

For more information: InNexus Biotechnology Amends Collaborative Agreement with the National Cancer Institute (NCI)